FOLH1 and posterior cortical atrophy: This approach capitalizes on the higher specificity of PSMA-PET/MRI in detecting primary PCa (pooled specificity of 81%) to counterbalance the inherently high false-positive rate of MRI, thus enabling patient reclassification and potentially avoiding unnecessary biopsies [91].